- Home
- AEON vs BIVI Comparison
AEON vs BIVI Comparison
Compare AEON & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEON | BIVI |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0M | 12.7M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | AEON | BIVI |
|---|---|---|
| Price | $0.23 | $1.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $1.82 | ★ $5.26 |
| AVG Volume (30 Days) | ★ 1.2M | 207.6K |
| Earning Date | 11-13-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.83 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.18 | $0.82 |
| 52 Week High | $1.45 | $3.79 |
Technical Indicators
Market Signals| Indicator | AEON | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 42.66 | 42.04 |
| Support Level | $0.24 | $1.28 |
| Resistance Level | $0.33 | $1.32 |
| Average True Range (ATR) | 0.03 | 0.10 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 13.30 | 42.39 |
Price Performance
Historical ComparisonAbout AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.